Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase DeficiencyBusiness Wire • 06/01/23
Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss EstimatesZacks Investment Research • 05/09/23
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline ProgressBusiness Wire • 05/09/23
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023Business Wire • 04/26/23
Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/28/23
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline ProgressBusiness Wire • 03/28/23
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023Business Wire • 03/07/23
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic FibrosisBusiness Wire • 01/31/23
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/19/22
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus TherapeuticsPRNewsWire • 12/12/22
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/22
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline ProgressBusiness Wire • 11/09/22
Arcturus Therapeutics to Present at the Following Investor Conferences in NovemberBusiness Wire • 11/07/22
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?Zacks Investment Research • 11/04/22
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA VaccinesBusiness Wire • 11/01/22
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine TechnologyPRNewsWire • 11/01/22